Piperazinyl Derivatives Targeting CCR-1 Receptor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and autoimmune diseases, such as rheumatoid arthritis, lack effective agents that can specifically modulate the activity of MIP-1α and its receptor CCR-1, leading to inadequate management of symptoms and potential side effects.
Innovation Solution
Development of novel cyclic derivatives that act as antagonists or partial agonists/antagonists of MIP-1α or CCR-1 receptor activity, which can be administered to treat rheumatoid arthritis and transplant rejection by modulating chemokine activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory and autoimmune diseases are used, then general anti-inflammatory effects are achieved, but specific modulation of MIP-1α/CCR-1 activity is inadequate leading to side effects
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (formula I) that selectively target the CCR-1 receptor. By modifying chemical parameters such as the heterocyclic ring system, substituent groups (R1-R6), and molecular configuration, the invention achieves high specificity for MIP-1α/CCR-1 interaction while avoiding the non-specific effects of conventional anti-inflammatory drugs.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that specifically mediate the blocking of MIP-1α binding to CCR-1 receptor. These compounds act as selective antagonists, interfering with the specific chemokine-receptor interaction without affecting other inflammatory pathways, thereby reducing side effects while maintaining therapeutic efficacy.
2Reliability
If conventional anti-inflammatory drugs are administered, then broad anti-inflammatory activity is achieved, but efficacy in modulating specific chemokine activity is insufficient
Solution Approach 1:
The patent achieves enhanced chemokine modulation efficacy through precise parameter changes in molecular structure. The compounds of formula I feature specific heterocyclic cores with defined substituent patterns (R1-R6 groups at specific positions), molecular weight ranges, and structural configurations that optimize binding affinity to CCR-1 while maintaining drug-like properties.
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and structural features at particular locations within the molecule. The heterocyclic ring system with specific substituent groups (R1-R6) at defined positions creates localized interaction regions that specifically recognize and bind to CCR-1 receptor sites, enhancing selectivity and efficacy.
3Object-generated harmful factors
If MIP-1α/CCR-1 interaction is specifically targeted, then inflammatory responses are reduced with fewer side effects, but treatment options for transplant rejection and inflammatory diseases are currently limited
Solution Approach 1:
The patent achieves universality by developing a series of compounds (formula I) with variable substituent groups (R1-R6) that maintain core CCR-1 antagonistic activity while allowing adaptation to different therapeutic needs. The structural framework accommodates various functional groups and modifications, enabling the same mechanism to be applied across multiple indications including transplant rejection, rheumatoid arthritis, and other inflammatory conditions.
Solution Approach 2:
The patent uses parameter changes to optimize compounds for different therapeutic applications. By systematically varying molecular parameters such as hydrophobicity, molecular size, and functional group composition within the formula I framework, the invention creates a library of analogs with tailored properties for different disease states and administration routes.
Data Source
AI summary
The present application describes modulators of MIP-1α of formula (I):or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, T, W, R1, R4, R5, R5a and R5b are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.